esmo summit latin america 2019
play

ESMO SUMMIT LATIN AMERICA 2019 Clinical cases presentation Maria Ignez Braghiroli CONFLICT OF INTEREST DISCLOSURE Sub-title Institutional clinical research: Roche, Astra-Zeneca, MSD, BMS Paid honoraria Roche, MSD, Bayer CASE 1

0 downloads 1 Views 1,26 MB Size Report
  1. ESMO SUMMIT LATIN AMERICA 2019 Clinical cases presentation Maria Ignez Braghiroli

  2. CONFLICT OF INTEREST DISCLOSURE Sub-title Institutional clinical research:  Roche, Astra-Zeneca, MSD, BMS Paid honoraria Roche, MSD, Bayer 

  3. CASE 1 RAMT, 39 yo Male No significant previous medical history or family history 2014 – Change in bowel habits and blood in the stools Colonoscopy: nearly obstructive sigmoid lesion, no further alterations  Path: Invasive moderately differentiated adenocarcinoma (grade 2) in the sigmoid colon.

  4. CASE 1 RAMT, 39 yo Male PET-CT: FDG uptake in the thickened sigmoid segment (2h SUV = 10,7) and in multiple focal liver areas, the majority corresponding to hypoattenuating lesions measuring up to 2.8 cm (highest 2h SUV = 9,7).

  5. CASE 1 RAMT, 39 yo Male No significant previous medical history or family history 2014 – Change in bowel habits and blood in the stools Colonoscopy: nearly obstructive sigmoid lesion, no further alterations  Path: Invasive moderately differentiated adenocarcinoma (grade 2) in the sigmoid colon. 39yo male with sigmoid adenocarcinoma, metastatic to the liver

  6. CASE 1 RAMT, 39 yo Male No previous medical history 2014 – Change in bowel habits and blood in the stools Colonoscopy: nearly obstructive sigmoid lesion, no further alterations  Path: Invasive moderately differentiated adenocarcinoma (grade 2) in the sigmoid colon. Jan/2014 – Laparoscopic sigmoidectomy - pT3 pN2a  Path: Moderately differentiated adenocarcinoma invading the adipose tissue  Metastasis in 6/24 lymph nodes  MSS; RAS wt, BRAF wt

  7. CASE 1 RAMT, 39 yo Male No previous medical history 2014 – Change in bowel habits and blood in the stools Colonoscopy: nearly obstructive sigmoid lesion, no further alterations  Path: Invasive moderately differentiated adenocarcinoma (grade 2) in the sigmoid colon. Jan/2014 – Laparoscopic sigmoidectomy - pT3 pN2a  Path: Moderately differentiated adenocarcinoma invading the adipose tissue  Metastasis in 6/24 lymph nodes  MSS; RAS wt, BRAF wt FOLFIRINOX x 4 cycles

  8. CASE 1 RAMT, 39 yo Male PET-CT: Comparing to previous exam, there has been marked reduction in the size and FDG uptake in the liver lesions. It is not observed the previous uptake in the sigmoid (status post surgical resection)

  9. CASE 1 RAMT, 39 yo Male May/2014 – Segment 2, 3 e 4A resection and resection of segments 6,7 e 4B lesions  Path: Moderately differentiated tubular adenocarcinoma, free margins 39yo male with sigmoid adenocarcinoma, metastatic to the liver. s/p resection of primary tumor s/p FOLFIRINOX x 4 s/p resection of liver lesions

  10. CASE 1 RAMT, 39 yo Male May/2014 – Segment 2, 3 e 4A resection and resection of segments 6,7 e 4B lesions  Path: Moderately differentiated tubular adenocarcinoma, free margins FOLFOX to complete a total of 12 cycles

  11. CASE 1 RAMT, 39 yo Male Feb/2017 – Possible Segment IV recurrence.

  12. CASE 1 RAMT, 39 yo Male Feb/2017 – Possible Segment IV recurrence -> RFA Dec/2018 – Last F/U images performed: NED

  13. CASE 2 M.I.A.S, 54 yo female PMH: Depression Hep A in childhood. Negative HVC and HBV SH: Smokes for the past 10 years, 10-15 cigarrets/d Social alcohol use FH: Brother had metastatic melanoma Father died at 77 with gastric cancer Maternal cousin and paternal cousin had breast cancer at age 38

  14. CASE 2 M.I.A.S, 54 yo female History of altered bowel habits (daily diarrhea) for the previous 4 months. No weight loss Underwent EGD and colonoscopy that showed no alterations MRI showed a pancreatic lesion

  15. CASE 2 M.I.A.S, 54 yo female Dec/2016 EchoEGD: Hypoechoic heterogeneous lesion in the body of the pancreas measuring 3.0x3.0 cm, with irregular and poorly precise limits. The lesion abuts the celiac axis and splenomesenteric junction. No enlarged nodes Normal hepatocholedocus Pancreas tail atrophy. Normal Wirsung.

  16. CASE 2 M.I.A.S, 54 yo female Dec/2016 EchoEGD: Hypoechoic heterogeneous lesion in the body of the pancreas measuring 3.0x3.0 cm, with irregular and poorly precise limits. The lesion abuts the celiac axis and splenomesenteric junction. No enlarged nodes Normal hepatocholedocus Pancreas tail atrophy. Normal Wirsung.  FNA: Suspicious for malignancy

  17. CASE 2 M.I.A.S, 54 yo female

  18. CASE 2 M.I.A.S, 54 yo female

  19. CASE 2 M.I.A.S, 54 yo female

  20. CASE 2 M.I.A.S, 54 yo female Dec/2016 EchoEGD: Hypoechoic heterogeneous lesion in the body of the pancreas measuring 3.0x3.0 cm, with irregular and poorly precise limits. The lesion abuts the celiac axis and splenomesenteric junction. No enlarged nodes Normal hepatocholedocus Pancreas tail atrophy. Normal Wirsung.  FNA: Suspicious for malignancy 54yo female with LA-PDAC

  21. CASE 2 M.I.A.S, 54 yo female From Dec/2016 to May/2017 - FOLFIRINOX x 12 cycles May/2017 CT scan: Infiltrative solid lesion in the neck and body of pancreas measuring 3.0 cm, stable in comparison to the previous scan, determining diffuse tail atrophy. There is wide contact and signs of celiac axis infiltration and well as common hepati, splenic and left gastric arteries, diffusely irregular. It also determines a portal vein deformity

  22. CASE 2 M.I.A.S, 54 yo female From Dec/2016 to May/2017 - FOLFIRINOX x 12 cycles -> Stable disease Jun/2017 to Jul/2017: CRT 25 x 2.3Gy in the tumor + 25 x 1.8Gy regional lymphatics – (planed weekly Gemcitabine 100mg/m2)  Thrombocytopenia post week 1

  23. CASE 2 M.I.A.S, 54 yo female From Dec/2016 to May/2017 - FOLFIRINOX x 12 cycles -> Stable disease Jun/2017 to Jul/2017: CRT 25 x 2.3Gy in the tumor + 25 x 1.8Gy regional lymphatics – (planed weekly Gemcitabine 100mg/m2)  Thrombocytopenia post week 1 Sep/2017 CT scan: Solid and infiltrative lesion in the body of pancreas measuring 3.0 cm, stable in comparison to the previous scan, determining pancreatic duct dilatation and diffuse tail atrophy.

  24. CASE 3 TMMS 34yo female No significant previous medical history No smoking No alcohol use Maternal grandfather has colon cancer at age 89 Maternal grandmother had breast cancer at age 86

  25. CASE 3 TMMS 34yo female 2013 was diagnosed with perforated sigmoid adenocarcinoma metastatic to the liver, lung and ovaries Apr/2013 – underwent resection of sigmoid tumour, partial cystectomy and oophorectomy  Path: Invasive moderately differentiated adenocarcinoma  MSS, KRAS mutated codon 13 Apr/13 to Aug/13 – FOLFIRI + Bev x 10 cycles -> excelent response

  26. CASE 3 TMMS 34yo female

  27. CASE 3 TMMS 34yo female Sep/13 – Partial right hepatectomy + resection of left liver nodules + ileostomy reversal  Path: confirmed Invasive moderately differentiated adenocarcinoma

  28. CASE 3 TMMS 34yo female Sep/13 – Partial right hepatectomy + resection of left liver nodules + ileostomy reversal  Path: confirmed Invasive moderately differentiated adenocarcinoma Oct/13 – Resection of lung nodules (6 lesions in the R, 4 lesions in the L) No measurable disease after surgical procedures

  29. CASE 3 TMMS 34yo female Nov/13 to Dec/13 – FOLFOX x 4 cycles  POD in the peritoneum and liver Re-started on FOLFIRI + Bev x 10 cycles until Jun/14 Feb/14 – Foundation one: HER2 amplification Sep/14 – Re-started on FOLFIRI + Bev due to POD in the peritoneum. Completed 5 cycles and had a good clinical response 6 months later, got symptomatic again

  30. CASE 3 TMMS 34yo female Jul/15 to - May/18 – Trastuzumab + Pertuzumab + Capecitabine – 38 cycles

  31. CASE 3 TMMS 34yo female Jul/15 to - May/18 – Trastuzumab + Pertuzumab + Capecitabine – 38 cycles May/18 – POD in the lungs 

  32. CASE 3 TMMS 34yo female Jul/15 to - May/18 – Trastuzumab + Pertuzumab + Capecitabine – 38 cycles May/18 – POD in the lungs  XELOX+ Trastuzumab with stable disease 

  33. CASE 4 64yo female No significant previous medical history Jun/2017 – Diagnosis of right colon cancer Jun/2017 – Right hemicolectomy  Tubular well differentiated adenocarcinoma infiltrating the serosa  No compromised lymph nodes of a total 22  dMMR (absent MLH1 e PMS2); BRAF inconclusive.

  34. CASE 4 64yo female No significant previous medical history Jun/2017 – Right hemicolectomy – pT3N0  Tubular well differentiated adenocarcinoma infiltrating the serosa  No compromised lymph nodes of a total 22  dMMR (absent MLH1 e PMS2); BRAF inconclusive. Aug/2017 – Diagnosis of metastatic peritoneal disease in the right hypochondria invading the 1st and 3rd duodenal portions and ileum, besides large contact with gallbladder, measuring 11 cm.

  35. CASE 4 64yo female No significant previous medical history Jun/2017 – Right hemicolectomy – pT3N0  Tubular well differentiated adenocarcinoma infiltrating the serosa  No compromised lymph nodes of a total 22  dMMR (absent MLH1 e PMS2); BRAF inconclusive. Aug/2017 – Diagnosis of metastatic peritoneal disease in the right hypochondria invading the 1st and 3rd duodenal portions and ileum, besides large contact with gallbladder, measuring 11 cm.

  36. CASE 2 M.I.A.S, 54 yo female Nov/2017

  37. CASE 4 64yo female Nov/2017 – Started on Pembrolizumab 200mg/dose 64yo female with dMMR right colon cancer with a large peritoneal implant

  38. CASE 2 M.I.A.S, 54 yo female Feb/2019

Recommend Documents


esmo summit latin america 2019
ESMO SUMMIT LATIN AMERICA 2019

ESMO SUMMIT LATIN AMERICA 2019 Palliative Care - Clinical Cases Presentation

esmo summit latin america 2019
ESMO SUMMIT LATIN AMERICA 2019

ESMO SUMMIT LATIN AMERICA 2019 Prostate cancer Clinical cases discussion

esmo summit latin america 2019
ESMO SUMMIT LATIN AMERICA 2019 Breast

ESMO SUMMIT LATIN AMERICA 2019 Breast Cancer Clinical Cases Enrique Soto

esmo summit latin america 2019
ESMO SUMMIT LATIN AMERICA 2019

ESMO SUMMIT LATIN AMERICA 2019 Gynecological cancer Clinical Cases Eduardo

latin america transforming opportunity
Latin America transforming opportunity

Latin America transforming opportunity London 23 May 2007 HSBC in Latin

esmo summit russia 2019
ESMO SUMMIT RUSSIA 2019 Case report:

ESMO SUMMIT RUSSIA 2019 Case report: BRCA -associated pancreatic cancer

latin america
LATIN AMERICA 4th QUARTER 2016 LATIN

LATIN AMERICA OUTLOOK 4Q2016 OUTLOOK LATIN AMERICA 4th QUARTER 2016 LATIN

latin america
LATIN AMERICA 1st QUARTER 2017 LATIN

LATIN AMERICA OUTLOOK 1Q2017 OUTLOOK LATIN AMERICA 1st QUARTER 2017 LATIN

m amp a forecast latin america 1h17
M&A FORECAST LATIN AMERICA 1H17

Licensed to Oliver Hill - TTR - 2017.Jun.21 M&A FORECAST LATIN AMERICA

by domestic demand
by domestic demand Juan Ruiz BBVA

Latin America: growth held back by domestic demand Juan Ruiz BBVA Research

cryoclinics australia cca who are we and what do we do
Cryoclinics Australia (CCA) Who are we

Cryoclinics Australia (CCA) Who are we and what do we do? Cryoclinics

zafgen pws clinical trial program overview november 16
Zafgen PWS Clinical Trial Program

Zafgen PWS Clinical Trial Program Overview November 16, 2014 Disclaimers

updates and genx benchmark dose progress
Updates and GenX Benchmark Dose

Updates and GenX Benchmark Dose Progress Mina Shehee, PhD Head, Occupational

scholars research library der pharmacia lettre 2014 6 2
Scholars Research Library Der Pharmacia

Available online a t www.scholarsresearchlibrary.com Scholars Research Library

bret 1 assays for measuring beta arrestin recruitment as
BRET-1 assays for measuring

BRET-1 assays for measuring beta-arrestin recruitment as primary screening in

accreditatio ion of cell llular therapy
Accreditatio ion of Cell llular

The Foundation for the Accreditatio ion of Cell llular Therapy Phyllis I.

allogeneic stem cells for autoimmune disease the
Allogeneic Stem Cells for Autoimmune

Allogeneic Stem Cells for Autoimmune Disease: The Preferred Choice Rafael

changes to the regulation of autologous cells and tissues
Changes to the regulation of autologous

Changes to the regulation of autologous cells and tissues Dr Ian Prosser

catherine l radtke dvm rodolfo nino fong phd blanca p
Catherine L. Radtke, DVM; Rodolfo

CHARACTERIZATION AND OSTEOGENIC POTENTIAL OF EQUINE MUSCLE TISSUE AND

c c
C C C C IP LINI Improved survival

C C C C IP LINI Improved survival chances for critically ill patients

note for non commercial purposes only fatty acid
Note: for non-commercial purposes only

Note: for non-commercial purposes only Fatty acid composition in blood and

cbd and the endocannabinoid system objectives
CBD and the Endocannabinoid System

CBD and the Endocannabinoid System OBJECTIVES Gain understanding of